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Abstract (max. 250 words):  
Tumor budding is a robust prognostic parameter in colorectal cancer and can be used as an 
additional factor to guide patient management. Though backed by large bodies of data, a 
standardized scoring method is essential for integrating tumor budding in reporting protocols. The 
International Tumor Budding Consensus Conference (ITBCC) 2016 has proposed such a scoring 
system. The aim of this study is to validate the ITBCC method of tumor budding assessment on a 
well-characterized CRC cohort.  379 patients with resected Stage I-IV colorectal cancer were entered 
into the study. Tumor budding was scored by two pathologists according to the ITBCC 
recommendations on hematoxylin and eosin-stained slides and scored as BD1 (low-), BD2 
(intermediate-) and BD3 (high-grade). Analysis was performed using a 3-tier approach, a 2-tier 
approach (BD1+2 versus BD3) and budding as a continuous variable. High-grade tumor budding was 
associated with adverse clinicopathological features including higher pT, higher pN stage and higher 
TNM stage (all p <0.001) and poorer overall survival on univariate analysis (p=0.0251 for BD1/2/3, 
p=0.0106 for BD1+2 versus BD3 and p=0.0195 for continuous scores (HR 1.023 (95%CI: 1.004-1.043 
per bud)). In stage II cancers, BD3 was associated with poorer disease-free survival (p<0.01). Tumor 
budding assessed by the method proposed by the ITBCC is applicable to colorectal cancer resection 
specimens and can be used for widespread reporting in routine.   
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1. Introduction  
In colorectal cancer (CRC), TNM staging is the most important factor in determining prognosis and 
patient management [1].  However, a wide biological heterogeneity of individual tumors may 
account for considerable differences in tumor behavior seen in patients within the same stage. 
Therefore, additional biomarkers to better stratify outcome are sought after within certain patient 
groups.  In the avid search for such potential biomarkers in CRC, tumor budding has emerged as an 
especially robust and promising candidate.  
 
Tumor budding, defined as single tumor cells or small clusters of ≤4 tumor cells at the invasive front 
of CRC [2], is a morphologically visible sign of tumor dissemination and has been linked to epithelial-
to-mesenchymal (EMT)-like processes [3]. Most recently, transcriptome profiling studies have linked 
tumor buds with the mesenchymal type (Consensus Molecular Classification type 4, CMS 4) of CRC 
[4]. It is therefore not surprising that large bodies of data have consistently demonstrated tumor 
budding to be an independent adverse prognostic marker in CRC and associated with unfavourable 
clinico-pathological features, nodal and distant metastases [5-7].   
 
Due to its potential clinical implications, tumor budding has been especially well studied in two 
scenarios. In endoscopically resected pT1 CRC, tumor budding has been demonstrated to be a strong 
and independent predictor of nodal metastases, and may help select patients for segmental 
resection with lymphadenectomy [2, 8-11]. In stage II CRC patients, high-grade budding tumors have 
been shown to behave aggressively [2, 12] and similarly to stage III CRC [13-15], with shorter survival 
times and higher rates of recurrence; therefore, these patients may be offered adjuvant 
chemotherapy.  
  
Although the data in the literature would certainly support the integration of tumor budding in 
reporting protocols, the lack of a standardized scoring system has been one of the major barriers to 
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the routine reporting of tumor budding in CRC. The objective of the International Tumor Budding 
Consensus Conference (ITBCC) was to provide an evidence-based set of recommendations for such a 
standardized method [2]. Since published, the ITBCC guidelines have been included as an additional 
reporting parameter in the protocol of the College of American Pathologists (CAP) with the 
recommendation to report tumor budding in pT1 and stage II CRC [16].  
 
While largely based on the method proposed by Ueno et al [10], further validation studies should 
provide the basis for more solid implementation of the ITBCC method in CRC reporting. Therefore, 
the aim of this study was to validate the ITBCC method of tumor budding assessment in a large, well-
characterized CRC cohort.  
 
2. Materials and methods  
2.1. Patient cohort 
379 patients with primary CRC resected between 2002 and 2014 were entered into this study. 
Haematoxylin and eosin (H&E)-stained slides were re-reviewed by two expert gastrointestinal 
pathologists (A.L., H.D.) according to the UICC TNM 7th edition [1]  for pathological features. In 
addition to standard reporting elements, this included assessment of peritumoral inflammation 
(Klintrup-Mäkinen score) and tumor border configuration. The Klintrup-Mäkinen score was obtained 
by evaluating the overall inflammatory reaction at the invasive margin on a four-degree scale ranging 
from 0 (no increase of inflammatory cells) to 3 (very prominent inflammatory reaction with invariable 
and frequent destruction of cancer cell islets) [17]. Tumor border configuration was assessed 
according to Karamitopoulou et al [18] by scoring the percentage of infiltrating tumor margin in 5% 
increments.  Tumors were categorized as either right (caecum, ascending colon, hepatic flexure and 
transverse colon), left (splenic flexure, descending colon, sigmoid) or rectal based on surgical and 
pathological reports.  Exclusion criteria included pre-operative chemoradiotherapy, previous 
endoscopic resection, tumors with pure signet ring cell and mucinous histology in accordance with 
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the ITBCC guidelines and patients with time of death within 1 month after surgery. Patient follow-up 
was scheduled according to the recommendations of the Swiss Society of Gastroenterology for 
surgically resected colorectal tumors [19]. Follow-up data including overall survival (OS) time 
(available for all patients, median 127.6 months, 95%CI: 99-147) and disease free survival (DFS) time 
(available for 78 patients in subset analysis of stage II patients, mean 37.3 months) was obtained. 
Ethics approval was granted by the Cantonal Ethics Commission of Bern (KEK 2017-01803, Oct. 24, 
2017). 
 
2.2 Assessment of tumor budding  
Tumor budding was scored by two observers (H.D, and F.G.) according to the ITBCC 2016 
recommendations [2]: H&E-stained sections were scanned at medium power (10x) to identify the 
densest area of budding at the tumor front (‘hotspot’). Tumor buds were counted in this area at 20x 
magnification (Nikon Eclipse E600, 750 objective, field diameter of 0.25 mm, area of 1.227 mm2; 
Nikon AG Instruments, Egg, Switzerland). The bud count was divided by the normalization factor 
(1.563) relative to the specific microscope eyepiece field number (FN) diameter to determine the 
tumor bud count per 0.785mm2. The final bud count and the budding category (Bd 1: 0-4 buds, Bd2: 
5-9 buds, Bd3: 10 buds or more, Fig. 1) were recorded. Cases with pure mucinous or signet ring cell 
morphology were excluded from analysis. Selected cases were discussed at a multiheader 
microscope to obtain a consensus score. 
 
2.3 Mismatch repair protein (MMR) status 
Immunohistochemistry for mismatch repair (MMR) proteins MLH1, MSH2, MSH6 and PMS2 was 
available for 342 patients, and performed as previously described [20].  Markers were considered 
positive if any nuclear expression in tumor cells was seen. Tumors negative for at least one marker 
were considered MMR-deficient, and MMR-proficient if all markers were expressed in the tumor. 
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Since information on family history was unavailable, no attempt was made to further subdivide 
patients into Lynch syndrome or sporadic MSI. 
 
2.4 Statistical analysis  
Descriptive statistics for categorical and continuous variables were analysed. The differences 
between categorical histopathological features and BD categories was carried out using the Chi-
Square test. The association with continuous budding counts was analysed with the Wilcoxon Rank 
Sum test. For age and percentage of expanding tumor border configuration, the Pearson correlation 
analysis was performed. Log rank test and Kaplan-Meier method were used for univariate survival 
time analysis. OS and DFS were the endpoints of interest. Multivariate survival analysis was 
performed using Cox regression analysis. Hazard ratios (HR) and 95%CI were used to determine 
effect size. P-values were all two-sided and considered significant when p<0.05. 
 
 
3. Results 
3.1 Associations of tumor budding with clinicopathological features and survival 
Across all stages (n=379), tumor budding was low-grade (BD1) in 149 patients, intermediate-grade 
(BD2) 101 patients and high-grade (BD3) in 129 patients (illustrated in Fig 1A-D). Frequencies of each 
variable and associations with BD category (BD1, BD2 and BD3 separately), a 2-tier classification 
(BD1+2 vs. BD3) and continuous scores are included in Table 1. As expected, higher tumor budding 
grades were seen in patients having received post-operative therapy (BD1/2/3: p=0.032, BD1/2 vs. 
BD3: 0.0016 and 0.0044 for continuous scores, respectively), patients with higher pT-stage (<0.001, 
all), nodal metastases (p<0.001, all), more advanced TNM stage (p<0.001, all), higher tumor grade 
(BD1/2/3: p=0.002, BD1/2 vs. BD3: p=0.002 and p<0.001 for continuous scores, respectively), 
lymphatic invasion (p<0.001, all), venous invasion (p<0.001, all), perineural invasion (p<0.001, all). 
Higher tumor budding was inversely associated with expanding tumor border configuration (p<0.001, 
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all) and higher peritumoral inflammation (Klintrup-Mäkinen score; p=0.026, p=0.0048 and p=0.0258, 
respectively). No significant differences in BD scores were seen in different tumor sites and in MMR 
proficient vs deficient tumors.   
On univariate analysis, tumor budding was significantly associated with shorter overall survival times 
in a 3-tier (BD1 vs. BD2 vs. BD3, p=0.0251, Fig. 2A) and 2-tier approach (BD1-2 vs. BD3, p=0.0106, Fig. 
2B) and when taken as a continuous variable (HR 1.023 (95% CI: 1.004-1.043) per increased bud, 
p=0.0195). However, significant associations between tumor budding and survival were lost in 
multivariate analysis (Table 2) including BD category (p=0.0911), TNM stage (stage IV: p=0.0041) and 
postoperative therapy (p=0.1022).   
 
3.2 Analysis of tumor budding, clinicopathological features and survival in Stage II patients  
In stage II patients (n=109,) tumor budding was low-grade (BD1) in 54 (49.5%) patients, intermediate-
grade (BD2) in 31 (28.4%) patients and high-grade (BD3) in 24 (22.0%) patients. Frequencies of each 
variable and associations with BD category (BD1, BD2 and BD3 separately), a 2-tier classification 
(BD1+2 vs. BD3) and continuous scores can be found in Table 3. In univariate analysis, tumor budding 
was not associated with overall survival time but with 5-year disease-free survival (p=0.0084, Fig 2C). 
As only 11 patients received post-operative therapy, no conclusions regarding possible associations 
between tumor budding grade, postoperative therapy and survival could be made. 
 
4. Discussion  
In this study, we provide a validation of the ITBCC scoring method on a large, well-characterized 
mixed-stage CRC cohort. Assessed by this method and in line with previous results in the literature 
using similar and other scoring systems, tumor budding was associated with adverse clinico-
pathological features and survival both in the entire cohort and in a subset of stage II patients.  
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Although several different tumor budding scoring methods have been proposed in the literature, the 
ITBCC consensus scoring method is largely based on the system proposed by Ueno et al [10]. Key 
aspects of this proposal (hot-spot, 20x magnification and 0,785 mm2) were adopted by the Japanese 
Society for Cancer of the Colon and the Rectum (JSCCR) prior to the ITBCC, and routine reporting of 
tumor budding in pT1 tumors according to this method has been performed since 2009 [21] . Indeed, 
this system has been used in studies including large Japanese patient cohorts with pT1 CRC [11, 22]  
and by others with slight variations, such as an adapted HPF size of 0.95mm2 [23-25]. However, a 
standardized consensus approach such as provided by the ITBCC guidelines is essential for tumor 
budding to be validated, to compare study results and ultimately be used as a biomarker in routine 
diagnostics.  
 
One important aspect of the ITBCC recommendations is the separate reporting of tumor budding 
grade (BD 1,2 or 3) and the raw tumor bud count. As a numerical variable on a biological spectrum, 
continuous tumor bud counts are expected to provide more precise risk stratification than cut-offs 
alone (as seen in Table 1). It must also be emphasized that relevant cut-offs will vary according to the 
clinical endpoint of a certain scenario (nodal metastases for pT1 tumors where BD2 and BD3 are 
considered high-risk; and recurrence/survival in advanced tumors where only BD3 is considered a risk 
factor) [2]. Hence, a two-tier classification (BD1+2 vs. BD3) was preferred to better stratify patients in 
this cohort, where pT1 tumors were underrepresented (n=30) and therefore not analyzed separately.   
In this study using a mixed stage cohort including patients with distant metastases, tumor budding 
was not an independent prognostic factor on multivariate analysis including TNM stage. This 
expected result emphasizes the importance and relevance of accurate clinical and pathological 
staging in routine as a basis for complementary biomarker studies. In a separate analysis of stage II 
patients, tumor budding was significantly associated with shorter 5 year DFS but not with shorter OS. 
This finding must be interpreted with caution as only few events were observed in this relatively 
small patient group, but underlines DFS as a more meaningful survival parameter in stage II tumors.  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
9 
 
 
Tumor budding in CRC is a robust biomarker which is simple to use and can be assessed using routine 
light microscopy on H&E stained slides. The standardized method as proposed by the ITBCC 
consensus recommendations will hopefully pave the way of integrating tumor budding in reporting 
protocols as has recently been the case for the latest update of the CAP CRC checklist. Further 
validation studies such as we present here aim to promote more widespread integration of the ITBCC 
consensus method in standardized reporting of tumor budding in CRC.   
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Figure legends  
Figure 1: Tumor budding as assessed by the ITBCC 2016 guidelines. (A) No tumor budding and (B) 
low-grade tumor budding (both BD1, 0-4 tumor buds/0.785mm2). (C) Intermediate-grade tumor 
budding (BD2, 5-9 tumor buds/0.785mm2). (D) High-grade tumor budding (BD3, ≥10 tumor 
buds/0.785mm2). Arrows point to selected tumor buds in all images.  
 
Figure 2: Survival curves of CRC patients stratified by budding status. (A) Overall survival in all 
patients (n=379) with low- (BD1), intermediate- (BD2) and high-grade budding (BD3). (B) Overall 
survival in all patients (n=379) stratified by BD1+2 versus BD3. (C) Disease-free survival in Stage II 
patients (n=78) stratified by BD1+2 versus BD3.    
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
11 
 
Table 1: Patient characteristics (n=379) and association of tumor budding (BD category) with 
clinicopathological features 
 
Features  Frequency 
N (%) 
BD Category P-value P-value 
   BD1 BD2 BD3 BD1,2,3 BD1+2 
vs 3 
Continuous 
score 
         
Age (yrs) (n=379) Mean 69.6 70.0 69.3 69.4 0.9714 0.9008 0.4777 
Gender (n=379)         
 Female  150 (39.6) 59 
(39.6) 
32 
(31.7) 
59 
(45.7) 
0.0964 0.0782 0.4839 
 Male 229 (60.4) 90 
(60.4) 
69 
(68.3) 
70 
(54.3) 
   
Histological subtype 
(n=378) 
        
 Adenocarcinoma 319 (84.4) 121 
(81.8) 
86 
(85.2) 
112 
(86.8) 
0.5738 0.6446 0.3979 
 Mucinous 52 (13.8) 25 
(16.9) 
12 
(11.9) 
15 
(11.6) 
   
 Other 7 (1.9) 2 (1.4) 3 (3.0) 2 
(1.6) 
   
Tumor location 
(n=379) 
        
 Left 229 (60.4) 91 
(61.1) 
60 
(59.4) 
78 
(60.5) 
0.9655 0.9902 0.6809 
 Right 150 (39.6) 58 
(38.9) 
41 
(40.6) 
51 
(39.5) 
   
Post-operative 
therapy (n=232) 
        
 None 172 (74.1) 81 
(84.4) 
36 
(75.0) 
55 
(62.5) 
0.0032
a
 0.0016
 a
 0.0004
 a
 
 Treated 60 (25.9) 15 
(15.6) 
12 
(25.0) 
33 
(37.5) 
   
pT (n=378)         
 pT1 30 (7.9) 20(13.4) 6 (5.9) 4 
(3.1) 
<0.0001
a
 <0.0001
a
 <0.0001
 a
 
 pT2 47 (12.4) 23 
(15.4) 
14 
(13.9) 
10 
(7.8) 
   
 pT3 190 (50.1) 84 
(56.4) 
49 
(48.5) 
57 
(44.2) 
   
 pT4 111 (29.3) 21 
(14.2) 
32 
(31.7) 
58 
(45.0) 
   
pN (n=370)         
 pN0 185 (50.0) 98 
(67.1) 
52 
(52.5) 
35 
(28.0) 
<0.0001
a
 <0.0001
a
 <0.0001
 a
 
 pN1 115 (31.1) 38 
(26.0) 
35 
(35.4) 
42 
(33.6) 
   
 pN2 70 (18.9) 10 (6.9) 12 
(12.1) 
48 
(38.4) 
   
TNM stage (n=347)         
 I 57 (16.4) 34 
(24.8) 
16 
(17.2) 
7 
(6.0) 
<0.0001
a
 <0.0001
a
 <0.0001
 a
 
 II 109 (31.4) 54 
(39.4) 
31 
(33.3) 
24 
(20.5) 
   
 III 111 (32.0) 37 
(27.0) 
32 
(34.4) 
42 
(35.9) 
   
 IV 70 (20.2) 12 (8.8) 14 
(15.1) 
44 
(37.6) 
   
Tumor grade         
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(n=364) 
 G1 21 (5.8) 16 
(11.4) 
5 (5.0) 0 
(0.0) 
0.002
 a
 0.002
 a
 <0.0001
 a
 
 G2 264 (72.5) 97 
(68.8) 
76 
(76.0) 
91 
(74.0) 
   
 G3 79 (21.7) 28 
(19.9) 
19 
(19.0) 
32 
(26.0) 
   
Lymphatic invasion 
(n=362) 
        
 L0 146 (40.3) 94 
(65.7) 
36 
(38.3) 
16 
(12.8) 
<0.0001
a
 <0.0001
a
 <0.0001
 a
 
 L1 216 (59.7) 49 
(34.3) 
58 
(61.7) 
109 
(87.2) 
   
Venous invasion 
(n=365) 
        
 V0 213 (58.4) 107 
(74.3) 
56 
(58.3) 
50 
(40.0) 
<0.0001
a
 <0.0001
a
 <0.0001
 a
 
 V1 152 (41.6) 37 
(25.7) 
40 
(41.7) 
75 
(60.0) 
   
Perineural invasion 
(n=346) 
        
 Pn0 276 (79.8) 127 
(93.4) 
78 
(85.7) 
71 
(59.7) 
<0.0001
a
 <0.0001
a
 <0.0001
 a
 
 Pn1 70 (20.2) 9 (6.6) 13 
(14.3) 
48 
(40.3) 
   
MMR status 
(n=258) 
        
 MMR-deficient 36 (14.0) 10 
(10.9) 
11 
(14.9) 
15 
(16.3) 
0.5479 0.4172 0.3876 
 MMR-proficient 222 (86.1) 82 
(89.1) 
63 
(85.1) 
77 
(83.7) 
   
Klintrup-Mäkinen  
(n=304) 
        
 0 15 (4.9) 5 (3.9) 1 (1.3) 9 
(9.0) 
0.0206
 a
 0.0048
 a
 0.0258
 a
 
 1 137 (45.1) 61 
(48.0) 
37 
(48.1) 
39 
(39.0) 
   
 2 116 (38.2) 45 
(35.4) 
25 
(32.5) 
46 
(46.0) 
   
 3 36 (11.8) 16 
(12.6) 
14 
(18.2) 
6 
(6.0) 
   
Expanding tumor 
border (%) (n=298) 
Mean 46.5 61.5 42.4 30.9 <0.0001
a
 <0.0001
a
 <0.0001 
Overall survival 
time (months) 
(n=379) 
Median (95%CI) 127.6 (99-
147) 
103.2+-
5.7 
93.1+-
6.6 
67+-
4.2 
0.0251
a
 0.0106
 a
 0.0195
 a.b
 
a 
Statistically significant values (p<0.05). 
b
Increased HR per bud: 1.023 (95%CI: 1.004-1.043). Abbreviations: mismatch repair 
(MMR) 
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Table 2: Multivariate analysis of tumor budding (BD) category along with TNM stage and 
postoperative therapy 
 
Feature  HR (95%CI) P-value 
    
BD category BD1+2 1.0 0.0911 
 BD3 1.51 (0.94-2.42)  
    
TNM stage IV 1.0 0.0041 
 I 0.23 (0.08-0.62)  
 II 0.62 (0.33-1.15) 0.127 
 III 0.75 (0.43-1.3) 0.3214 
    
Postoperative therapy None 1.0 0.1022 
 Treated  0.65 (0.38-1.09)  
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Table 3: Association of tumor budding (BD category) with clinicopathological features in stage II 
patients (n=109) 
 
Features  Frequency 
N (%) 
BD Category P-value P-value 
   BD1 BD2 BD3 BD1,2,3 BD1+2 
vs 3 
Continuous 
score 
         
Age (yrs) (n=109) Mean 69.5 69.5 69.0 69.8 0.9471 0.7755 0.5387 
         
Gender (n=109) Female  48 (44.0) 23 
(43.6) 
11 
(35.5) 
14 
(58.3) 
0.2281 0.1101 0.422 
 Male 61 (56.0) 31 
(57.4) 
20 
(64.5) 
10 
(41.7) 
   
         
Histological subtype 
(n=109) 
Adenocarcinoma 89 (81.7) 44 
(81.5) 
25 
(80.7) 
20 
(83.3) 
0.6262 0.8593 0.5759 
 Mucinous 19 (17.4) 10 
(18.5) 
5 
(16.1) 
4 
(16.7) 
   
 Other 1 (0.9) 0 
(0.0) 
1 
(3.2) 
0 
(0.0) 
   
         
Tumor location (n=109) Left 56 (51.4) 33 
(61.1) 
12 
(38.7) 
11 
(45.8) 
0.1145 0.5384 0.1633 
 Right 53 (48.6) 21 
(38.9) 
19 
(61.3) 
13 
(54.2) 
   
         
Post-operative therapy 
(n=68) 
None 57 (83.8) 32 
(88.9) 
13 
(81.3) 
12 
(75.0) 
0.4321 0.2731 0.1723 
 Treated 11 (16.2) 4 
(11.1) 
3 
(18.8) 
4 
(25.0) 
   
         
pT (n=109) pT3 88 (80.7) 48 
(88.9) 
24 
(77.4) 
16 
(66.7) 
0.0614 0.0478 0.0846 
 pT4 21 (19.3) 6 
(11.1) 
7 
(22.6) 
8 
(33.3) 
   
         
Tumor grade (n=105) G1 6 (5.7) 4 
(8.0) 
2 
(6.5) 
0 
(0.0) 
0.1851 0.0497 0.5626 
 G2 83 (79.1) 41 
(82.0) 
25 
(80.7) 
17 
(70.8) 
   
 G3 16 (15.2) 5 
(10.0) 
4 
(12.9) 
7 
(29.2) 
   
         
Lymphatic invasion 
(n=103) 
L0 69 (67.0) 41 
(82.0) 
19 
(63.3) 
9 
(39.1) 
0.0013 0.0013 0.0003 
 L1 34 (33.0) 9 
(18.0) 
11 
(36.7) 
14 
(60.9) 
   
         
Venous invasion (n=104) V0 79 (76.0) 44 
(86.3) 
19 
(63.3) 
16 
(69.6) 
0.0472 0.416 0.0572 
 V1 25 (24.0) 7 
(13.7) 
11 
(36.7) 
7 
(30.4) 
   
         
Perineural invasion (n=99) Pn0 90 (90.9) 47 
(97.9) 
27 
(93.1) 
16 
(72.7) 
0.0027 0.0008 0.0023 
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 Pn1 9 (9.1) 1 
(2.1) 
2 
(6.9) 
6 
(27.3) 
   
         
MMR status (n=66) MMR-deficient 12 (18.2) 3 
(9.7) 
5 
(27.8) 
4 
(23.5) 
0.229 0.507 0.1581 
 MMR-proficient 54 (81.8) 28 
(90.3) 
13 
(72.2) 
13 
(76.5) 
   
         
Klintrup-Mäkinen  (n=89) 0 2 (2.3) 0 
(0.0) 
0 
(0.0) 
2 
(10.5) 
0.1818 0.0429 0.0306 
 1 38 (42.7) 22 
(47.8) 
9 
(37.5) 
7 
(36.8) 
   
 2 40 (45.0) 19 
(41.3) 
12 
(50.0) 
9 
(47.4) 
   
 3 9 (10.1) 5 
(10.9) 
3 
(12.5) 
1 
(5.3) 
   
         
Expanding tumor border 
(%) (n=109) 
Mean 56.7 67.4 42.8 47.3 0.0023 0.1526 <0.0001 
Abbreviations: mismatch repair (MMR) 
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Highlights:  
- The ITBCC 2016 has initiated the inclusion of tumor budding in CRC reporting protocols 
- Validation studies provide further ground to implement the ITBCC scoring system in routine 
- ITBCC tumor budding is recommended as an additional prognostic factor in CRC    
ACCEPTED MANUSCRIPT
Figure 1
Figure 2
